10:43 AM EST - Neovasc Inc. : Announced receipt of an Administrative Acceptance Review Notification for the Company's Premarket Approval application from the U.S. Food and Drug Administration for its Neovasc Reducer™ medical device for the treatment of refractory angina. Neovasc Inc.
shares T.NVCN are trading up $0.28 at $4.33.
